Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.72 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | DRD2 | P14416 | 10/20 | 0.68 |
| ▸ | HTR6 | P50406 | 10/20 | 0.68 |
| ▸ | HTR1A | P08908 | 9/20 | 0.68 |
| ▸ | HTR7 | P34969 | 9/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tepirindole SCHEMBL29710897 | 1.00 | SLC6A4 (0.72) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| Tepirindole SCHEMBL11307437 | 1.00 | SLC6A4 (0.72) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| SCHEMBL11327571 | 0.91 | OPRM1 (0.73) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| Hydrochloric Acid SCHEMBL11320856 | 0.91 | OPRM1 (0.73) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| SCHEMBL10366941 | 0.88 | OPRM1 (0.71) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| SCHEMBL15064205 | 0.88 | OPRM1 (0.71) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| SCHEMBL791317 | 0.86 | DRD2 (0.69) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| SCHEMBL11224825 | 0.86 | DRD2 (0.69) | SLC6A4OPRM1OPRK1DRD2HTR6 | |
| Hydrochloric Acid SCHEMBL11233239 | 0.86 | KDM4E (0.57) | SLC6A4OPRM1OPRK1DRD2HTR1A | |
| SCHEMBL793144 | 0.85 | DRD2 (0.71) | SLC6A4OPRM1OPRK1DRD2HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| US-20090220611-A1 | Microparticles With Modified Release of At Least One Active Principle and Oral Pharmaceutical Form Comprising Same | FLAMEL TECHNOLOGIES, S.A. (FR) | 2009-09-03 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| EP-1931320-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | Flamel Technologies (FR) | 2008-06-18 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| WO-2007036671-A2 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL GALENIC FORM COMPRISING SAME | FLAMEL TECHNOLOGIES (FR) | 2007-04-05 | — | — | WO | claimed |
| US-20060024365-A1 | Novel dosage form | VAYA NAVIN | 2006-02-02 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-4706683-A2 | CHEWABLE FORMULATIONS | Elanco Tiergesundheit AG (CH) | 2026-03-11 | — | — | EP | disclosed |
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-5795909-A | ANTICARCINOGENIC AND ANTITUMOR AGENTS; BREAST, COLON, OVARIANCANCERS | NEUROMEDICA, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| EP-0003199-B1 | TETRAHYDROPYRIDINYL INDOLE DERIVATIVES AND THEIR SALTS, PROCESS FOR THEIR PREPARATION, THEIR USE AS MEDICINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | ROUSSEL-UCLAF (FR) | 1981-11-11 | — | — | EP | disclosed |
| EP-0003199-A2 | Tetrahydropyridinyl indole derivatives and their salts, process for their preparation, their use as medicines and pharmaceutical compositions containing them | ROUSSEL-UCLAF (FR) | 1979-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | SLC6A4 120/4885OPRM1 1993/4885OPRK1 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.